Holen Sie sich die Stockscreener-App
0.7181
10.20%
-0.0816
VolitionRX Ltd Aktie (VNRX) Neueste Nachrichten
VolitionRX Ltd (VNRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VolitionRX Ltd (VNRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VolitionRX Ltd (VNRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
VolitionRX Ltd (VNRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
VolitionRX Ltd (VNRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
VNRX|VolitionRX Ltd|Price:0.890|Chg%:-0.110 - TradingKey
VolitionRX Ltd (VNRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VolitionRX Ltd (VNRX) Balance Sheet - TradingKey
VolitionRX Ltd (VNRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VNRX|VolitionRX Ltd|Price:1.000|Chg%:-0.070 - TradingKey
TradingKey - TradingKey
VolitionRx Limited Amends Certificate of Incorporation: SEC Filing Details and XBRL Data 10 - Minichart
VOLITIONRX LTD SEC Filing (Jul 20, 2026) - Stock Titan
VolitionRx (VNRX) Stock Gets Fair Value Boost As Analysts Split On Nu.Q Execution - Yahoo Finance
VolitionRX (VNRX) Registration filing Summary - Quartr
VNRX Announces Sale of 3.31 Million Shares by Selling Stockholders - GuruFocus
VolitionRx (NYSE: VNRX) files to register 3.3M Lind-linked shares for resale - Stock Titan
Maxim Group Maintains VolitionRX(VNRX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
VolitionRx Ltd explores blood-based cancer diagnostics as investors watch VNRX - ad-hoc-news.de
VolitionRx releases lung cancer prognostic study data - Investing.com
VolitionRx releases lung cancer prognostic study data By Investing.com - Investing.com Australia
VolitionRx’s lung cancer test could help doctors predict outcomes - Stock Titan
VolitionRX Announces Data Showing the Prognos - Moomoo
VolitionRx prices $4.6 million public offering at $1.55 per share By Investing.com - Investing.com UK
VolitionRX Ltd Actuals & Estimates (AMEX:VNRX) - TradingView
VNRX Forecast — Price Target — Prediction for 2027 - TradingView
What Sysmex (TSE:6869)'s Nu.Q NETs Collaboration With VolitionRx Means For Shareholders - simplywall.st
VolitionRX Ltd (VNRX) Institutional Confidence - TradingKey
VOLITIONRX ANNOUNCES PRICING OF $4.6 MILLION PUBLIC OFFERING - Moomoo
VolitionRX Ltd (VNRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
VNRX Reinstated by Maxim Group -- Price Target Announced at $4.0 - GuruFocus
VolitionRx Limited 8-K Filing: Key Corporate Details and SEC Registration for June 2026 - Minichart
VolitionRx (NYSE: VNRX) issues stock to Lind for note repayments - Stock Titan
VolitionRx (VNRX) Receives Buy Rating with $4 Price Target from Maxim - GuruFocus
VolitionRx Limited (VNRX) Partners with Sysmex to Enhance Diagno - GuruFocus
Sysmex (TSE:6869) Stock Could Be 17.8% Undervalued After VolitionRx Collaboration - simplywall.st
VolitionRx (VNRX) Forms Partnership with Sysmex for Assay Optimi - GuruFocus
VolitionRx partners with Sysmex on diagnostic test development By Investing.com - Investing.com Nigeria
VolitionRx partners with Sysmex on diagnostic test development - Investing.com
VolitionRx partners with Sysmex to optimize NETs test for sepsis and other diseases - Stock Titan
VolitionRx Ltd Stock (US92852X1037): Quarterly earnings keep early-detection biotech in focus - Ad-hoc-news.de
VolitionRx Enters Securities Purchase Agreement With Investors to Raise Capital - TradingView
VolitionRx (NYSE: VNRX) prices $4.6M stock offering with $2.3M warrant upside - Stock Titan
VolitionRx (NYSE: VNRX) to Offer 2.96M Shares and 1.48M Warrants - Stock Titan
VolitionRx stock tumbles on $4.6M offering priced at discount By Investing.com - Investing.com Nigeria
0.55%
2.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):